secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001104659-23-035380
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics reports FY2022 net loss of $29.9M; cash runs into Q3 2023; suspends frank relapse enrollment
--------------------------------------------------------------------------------

- Net loss $29.9M for FY2022, improved from $41.9M in prior year.
- Cash and cash equivalents $11.8M at Dec 31, 2022; expected to fund operations into Q3 2023.
- Suspended enrollment of frank relapse patients in ARTEMIS trial after no objective responses; re-evaluating modifications.
- MT-401 showed MRD+ responses: one patient bridged to transplant, another with 70% PCR reduction; data expected H2 2023.
- Wilson Wolf services agreement provided $8M upfront; Lincoln Park equity facility for up to $25M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923035380/0001104659-23-035380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923035380/tm239491d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-035380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer